{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Infection&page=44",
    "query": {
      "intervention": "Infection",
      "page": 44
    },
    "page_size": 10
  },
  "pagination": {
    "page": 44,
    "page_size": 10,
    "total_count": 5232,
    "total_pages": 524,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Infection&page=45&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Infection&page=43&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-02T23:34:09.621Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02996461",
      "title": "VRC 320: A Phase I, Randomized Clinical Trial to Evaluate the Safety and Immunogenicity of a Zika Virus DNA Vaccine, VRC-ZKADNA090-00-VP, Administered Via Needle and Syringe or Needle-free Injector, PharmaJet, inHealthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Prevention of Zika Infection",
        "Zika-Specific Immune Response"
      ],
      "interventions": [
        {
          "name": "VRC-ZKADNA090-00-VP",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 45,
      "start_date": "2016-12-12",
      "completion_date": "2019-09-03",
      "has_results": false,
      "last_update_posted_date": "2019-12-17",
      "last_synced_at": "2026-11-02T23:34:09.621Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02996461"
    },
    {
      "nct_id": "NCT02312219",
      "title": "PET/CT Imaging Companion Study To ACTG A5314",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "HIV",
        "Inflammation",
        "Atherosclerosis"
      ],
      "interventions": [
        {
          "name": "Folic Acid",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Low Dose Methotrexate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 35,
      "start_date": "2014-11",
      "completion_date": "2016-12-08",
      "has_results": true,
      "last_update_posted_date": "2019-02-06",
      "last_synced_at": "2026-11-02T23:34:09.621Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02312219"
    },
    {
      "nct_id": "NCT04366830",
      "title": "Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC) for Acute Respiratory Distress Syndrome (ARDS) Due to COVID-19 Infection",
      "overall_status": "NO_LONGER_AVAILABLE",
      "study_type": "EXPANDED_ACCESS",
      "phases": [],
      "conditions": [
        "Moderate to Severe Acute Respiratory Distress Syndrome Associated With COVID-19"
      ],
      "interventions": [
        {
          "name": "Remestemcel-L",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mesoblast International Sàrl",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2021-02-18",
      "last_synced_at": "2026-11-02T23:34:09.621Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04366830"
    },
    {
      "nct_id": "NCT01701219",
      "title": "Safety and Efficacy Study of Ceftaroline in Subjects With Staphylococcus Aureus Bacteremia or With Persistent Methicillin-Resistant Staphylococcus Aureus Bacteremia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Staphylococcus Aureus Bacteremia",
        "Methicillin-resistant Staphylococcus Aureus (MRSA) Bacteremia"
      ],
      "interventions": [
        {
          "name": "Ceftaroline fosamil",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Forest Laboratories",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 56,
      "start_date": "2013-01",
      "completion_date": "2014-07",
      "has_results": false,
      "last_update_posted_date": "2014-07-31",
      "last_synced_at": "2026-11-02T23:34:09.621Z",
      "location_count": 27,
      "location_summary": "Birmingham, Alabama • Sacramento, California • San Francisco, California + 23 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Sylmar",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01701219"
    },
    {
      "nct_id": "NCT00009009",
      "title": "Kidney Transplant for HIV-Infected Patients in Renal Failure",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Kidney Failure",
        "HIV Infection"
      ],
      "interventions": [
        {
          "name": "immunosuppressive regimen designed to complement HAART",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 10,
      "start_date": "2001-01",
      "completion_date": "2002-12",
      "has_results": false,
      "last_update_posted_date": "2008-03-04",
      "last_synced_at": "2026-11-02T23:34:09.621Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00009009"
    },
    {
      "nct_id": "NCT04240509",
      "title": "Defining the PrEP Care Continuum Among Recently Incarcerated Men at High-Risk for HIV Infection",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "HIV Infections",
        "Sexually Transmitted Diseases"
      ],
      "interventions": [
        {
          "name": "Emtricitabine / Tenofovir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The Miriam Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 100,
      "start_date": "2019-11-01",
      "completion_date": "2021-12-31",
      "has_results": false,
      "last_update_posted_date": "2021-02-23",
      "last_synced_at": "2026-11-02T23:34:09.621Z",
      "location_count": 1,
      "location_summary": "Providence, Rhode Island",
      "locations": [
        {
          "city": "Providence",
          "state": "Rhode Island"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04240509"
    },
    {
      "nct_id": "NCT04388163",
      "title": "Gentian Violet Treatment for Hidradenitis Suppurativa",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hidradenitis Suppurativa"
      ],
      "interventions": [
        {
          "name": "Gentian Violet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Wake Forest University Health Sciences",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 0,
      "start_date": "2025-08",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2025-09-04",
      "last_synced_at": "2026-11-02T23:34:09.621Z",
      "location_count": 1,
      "location_summary": "Winston-Salem, North Carolina",
      "locations": [
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04388163"
    },
    {
      "nct_id": "NCT04966871",
      "title": "Safety, Tolerability and Efficacy of PfSPZ Vaccine Against Heterologous CHMI in US Malaria naïve Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Malaria"
      ],
      "interventions": [
        {
          "name": "PfSPZ Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "PfSPZ Challenge (7G8) for CHMI",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Normal Saline",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Sanaria Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 54,
      "start_date": "2021-09-27",
      "completion_date": "2022-06-21",
      "has_results": false,
      "last_update_posted_date": "2022-07-18",
      "last_synced_at": "2026-11-02T23:34:09.621Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04966871"
    },
    {
      "nct_id": "NCT01057121",
      "title": "Lenalidomide in Treating Patients With AIDS-Associated Kaposi's Sarcoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "AIDS-Related Kaposi Sarcoma",
        "Recurrent Kaposi Sarcoma"
      ],
      "interventions": [
        {
          "name": "Lenalidomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 38,
      "start_date": "2010-08-27",
      "completion_date": "2014-08-04",
      "has_results": true,
      "last_update_posted_date": "2022-02-08",
      "last_synced_at": "2026-11-02T23:34:09.621Z",
      "location_count": 13,
      "location_summary": "Los Angeles, California • San Diego, California • San Francisco, California + 9 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Honolulu",
          "state": "Hawaii"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01057121"
    },
    {
      "nct_id": "NCT05031078",
      "title": "Assessing Durable Antibody Response to HPV Vaccination",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "HPV"
      ],
      "interventions": [
        {
          "name": "Gardasil-9",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Lidocaine injections",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 17,
      "start_date": "2021-12-21",
      "completion_date": "2026-03-26",
      "has_results": true,
      "last_update_posted_date": "2026-08-20",
      "last_synced_at": "2026-11-02T23:34:09.621Z",
      "location_count": 2,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05031078"
    }
  ]
}